Evidence for Rescheduling Hydrocodone Combination Products?

Published Online: Thursday, January 9, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, argues that there is no evidence to support categorizing hydrocodone combination products as Schedule II drugs rather than Schedule III drugs.

This is the part of a series of videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. To see the first video in the series, in which Dr. McPherson discusses the dramatic increase in the use of opioids in the United States, click here. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)

These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Deaths related to oxycodone overdose dropped 25% in Florida after the state adopted a Prescription Drug Monitoring Program to track controlled substance dispensing.
The FDA today expanded the indication of Allergan’s onabotulinumtoxinA (Botox), allowing the drug to be used for the treatment of upper limb spasticity in adults.
In addition to relieving pain, acetaminophen may cause patients to experience less intense emotional responses.
The FDA is warning pharmacists that pets are at risk of death when exposed to topical pain medications containing flurbiprofen.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$